Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
TScan Therapeutics, Inc. Banner

TScan Therapeutics, Inc.

TCRX Stock Analysis

Page title

Section title

Breakdown
2019
2020
2021
2022
2023
Net Income
-13.658m-26.127m-48.625m-66.221m-89.218m
Depreciation & Amortization
519.000K1.230M3.328M5.137M5.361M
Change in Working Capital
299.000K21.357M-5.896m-10.230m17.606M
Operating Cash Flow
-12.522m-3.023m-48.677m-66.503m-61.358m
Capital Expenditure
-1.247m-4.238m-9.941m-4.225m-3.146m
Free Cash Flow
-13.769m-7.261m-58.618m-70.728m-64.504m
Debt Repayment
0.0000.0000.000-324.000k0.000
Dividends Paid
0.0000.0000.0000.0000.000
Common Stock Issued
34.812M288.000K89.647M193.000K135.443M
Common Stock Repurchased
0.0000.0000.0000.0000.000
Net Change in Cash
21.043M-6.973m131.050M-41.372m13.332M